Lu Alleruzzo’s Post

"We are grateful to Dr. Nick Shaheen and his co-investigators for this valuable contribution to the clinical evidence supporting EsoGuard esophageal precancer testing," said Victoria T. Lee, M.D., Lucid's Chief Medical Officer. "This second multi-center clinical validation study in an intended use screening population demonstrates nearly identical EsoGuard performance compared to two previously reported National Cancer Institute (NCI)-funded case-control studies—a multi-center pivotal study published in Science Translational Medicine introducing the technology and a multi-center study from the BETRNet consortium recently published in the American Journal of Gastroenterology. Additionally, the previously announced and now peer-reviewed results of the Cleveland VA screening study demonstrated an identical NPV, and a similar sensitivity of 92.9%. Collectively, these four clinical validity studies demonstrate an unprecedented performance of a molecular diagnostic test in detecting a precancer. They strongly support EsoGuard's use as a widespread screening tool to prevent esophageal cancer through the early detection of esophageal precancer." Read more here: https://lnkd.in/gDGYqnJD #EarlyDetection #CancerPrevention

📆In just one month, we will be hosting the VI Conference on Translational Research on Urological Tumours at the BCIN Badalona, presented in a dynamic hybrid format—both virtual and in-person. 🔍The primary goal of this conference is to delve into the intricacies of urological tumours through the lens of translational and clinical research. Over the course of these two days, 20 esteemed national and international experts in urological tumour treatment and research will provide comprehensive updates and reviews on pivotal research lines. Topics include mechanisms of therapy resistance, exploration of new potential biomarkers, breakthroughs in immunotherapy, innovative preclinical tools for translational research, and promising therapies in urologic tumours. 👥 The conference is designed for professionals engaged in the diagnosis and treatment of urological tumours, as well as translational researchers with a keen interest in this area of oncology. Don't miss this opportunity to connect with leading experts, gain valuable insights, and stay at the forefront of urological tumours research! 🆓 Register for free at: [email protected] Germans Trias i Pujol Research Institute (IGTP); Catalan Institute of Oncology #UrologicalTumours #TranslationalResearch #OncologyConference #MedicalResearch #prostatecancer #bladdercancer #kidneycancer #immunotherapy #biomarkers #oncologyresearch #oncology #oncología #BCIN

The DATA keeps rolling in!! Yet another clinical validation study (the fourth, including three peer-reviewed in prestigious journals and one under review) telling the SAME exact story—#EsoGuard performed on samples collected with #EsoCheck has unprecedented performance at detecting #esophageal precancer including early stage (non-dysplastic BE, NDBE) and short (1-3 cm) segments of disease (SS-NDBE). This study’s Negative Predictive Value (NPV) of ~99% provides providers very high confidence that EsoGuard-negatives patients do not have precancer/cancer and its Postive Predictive Value of ~30% demonstrates EsoGuard’s strong clinical utility as a triage test, increasing the positive yield of endoscopy 3-fold and eliminating the need for expensive and invasive endoscopy in the vast majority of at-risk patients recommended for esophageal precancer screening to prevent #esophagealcancer. #earlydetectionsaveslives #cancerprevention #checkyourfoodtube Lucid Diagnostics Nick Shaheen Victoria T. Lee Suman Verma Shaun O'Neil Brian J. deGuzman, MD

November is #LungCancer Awareness month 🫁 📣 Check out this NEW interview from #ESMO2023 | DARWIN II: deciphering anti-#tumor response & resistance to IO w/ intratumour #heterogeneity in #NSCLC 🎥 Crispin Hiley, PhD, CURE CANCER @ UCL CANCER INSTITUTE, shares an overview of the Phase II #DARWIN II trial (NCT02314481), a multicenter, molecularly stratified trial designed to investigate how intratumor #heterogeneity influences treatment response in patients with #NSCLC 🧬 ⭐ The DARWIN II trial enrolled 65 patients with metastatic #NSCLC who had previously participated in the #TRACERx #LungCancer observational cohort study ⭐ They received #atezolizumab or #atezolizumab with #chemotherapy. Multi-omic analysis of primary #tumor and relapse #biopsies revealed that a high #clonalmutation burden was associated with a significantly improved response ⭐ Novel molecular features, including intratumor #heterogeneity of the transcriptome and #DNA #methylation, were also linked to #immunotherapy response This study marks the first to prospectively show that #clonal mutations and specific #molecular features can predict #immunotherapy outcomes in patients with #NSCLC 🔦 Give it a watch to learn more 👉 https://lnkd.in/eHJQtgPu #Oncology ESMO - European Society for Medical Oncology #LungCancerAwarenessMonth #LCsm

Imaging to identify prostate cancer recurrence risk: Glad to share our first paper published in Proceedings of the National Academy of Sciences (#PNAS) journal with our collaborator from the University of Cambridge, the Department of Radiology of Addenbrooke’s Hospital, Nikita Sushentsev, Mary A. McLean, Ines Horvat-Menih, Vinay Ayyappan, Ian Mills, Anne Y. Warren, Vincent Gnanapragasam Ferdia Gallagher, Tristan Barret and my colleagues from AstraZeneca, Jack Richings, Simon Barry and Richard Goodwin In this paper, we demonstrated that imaging lactate in tumours with #MRI and spatial metabolomics (Mass Spec Imaging #MSI, IMSIS Conference)  could identify prostate cancer patients susceptible to biochemical recurrence (BCR) following surgical prostate removal in a prospective study involving 21 participants; the results suggest that this method could be developed to better inform prostate cancer treatment decision making, particularly for patients with intermediate-risk cancers. Link to the paper: https://lnkd.in/ezebHZ7n #WhatScienceCanDo #spatialbiology #pharmaceuticals #massspectrometry #molecularimaging #cancerresearch #clinicalresearch #oncology #Prostatecancer #MedicalImaging

With exam season coming to an end I would like to share my poster presentation supervised by Sophia Semerdjieva, Nirusha Weerasinghe PhD, RSci, CBio, AFHEA, FIBMS at University of East London. It was based on the role of Hypoxia Inducible Factor–1α (HIF-1α) in the formation of vascular mimicry (VM) in high-grade and high-stage colorectal cancer. Key findings include: 🔬 Vascular Mimicry (VM): VM formation, where cancer cells develop blood vessel-like channels, is linked with aggressive tumors and poor prognosis. 🧬 Cell Line Studies: HCT116 cells, known for higher invasiveness and motility, demonstrated significant VM capability and elevated HIF-1α and EMT marker expression under hypoxic conditions. In contrast, HT29 cells showed a more epithelial phenotype with higher E-cadherin and Claudin-4 expression. ⚙️ Hypoxia’s Role: Hypoxic conditions were found to increase HIF-1α protein expression, promoting VM formation and correlating with aggressive cancer behavior. 🏥 Therapeutic Potential: Targeting the HIF-1α/EMT pathway could be a promising therapeutic approach for colorectal cancer metastasis. This research underscores the importance of understanding VM and EMT in colorectal cancer progression, opening doors for new therapeutic strategies. #ColorectalCancer #CancerResearch #Hypoxia #EMT #VascularMimicry #Oncology #HIF1α #CancerTherapy

🫁🔬🧑⚕️ Exciting new findings by Prof Susanne Kossatz and the team at Technical University of Munich published in #EJNMMI are shedding light on potential treatment advancements for Small Cell Lung Cancer (#SCLC), a highly aggressive tumor of neuroendocrine origin. Despite frequent expression of somatostatin receptor type 2 (SSTR2) in SCLC, the clinical benefit of SSTR2-targeted radionuclide therapies has been limited. However, recent research suggests a promising strategy: combining SSTR2-targeted therapy with a PARP inhibitor (PARPi). This study discovered: 🩻 Enhanced Potency: Combining [177Lu]Lu-DOTA-TOC with PARPi resulted in a 2.9- to 67-fold increase in potency compared to [177Lu]Lu-DOTA-TOC alone. 🧬 Increased DNA Damage: Combination treatment led to decreased clonogenic survival and higher levels of persistent DNA damage. 📉 Improved Tumor Control: In vivo, combination therapy significantly slowed tumor growth and improved median survival rates compared to monotherapies or untreated controls. These findings highlight the potential of PARPi to enhance the effectiveness of SSTR2-targeted PRRT in SSTR2 low-expressing SCLC tumors, paving the way for new treatment options. 🔗 Learn more about the study here: https://lnkd.in/gNcC42pB Congratulations to the researchers for their innovative approach and impactful results!👏 Further evaluation in human trials could bring us one step closer to better treatment outcomes for SCLC patients. #SCLC #CancerResearch #Oncology #RadionuclideTherapy #PARPInhibitors #ClinicalTrials #MedicalResearch

The 14th "Milan Congress on Anticancer Innovative Therapy" Conference will involve leading international experts in the field of immuno-oncology and biologic therapy of cancer to improve the potential, opportunities and challenges of the new approaches. The increasing knowledge of the molecular mechanisms responsible for neoplastic progression, the characterization of tumor microenvironment, and the immunological/angiogenetic mechanisms regulating the tumor-host interaction, allowed us to identify and apply more effective anti-cancer biogical and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorythms of several different tumor types. This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy, for example in the neoadjuvant setting of melanoma patients. Finally, a wide spectrum of evolving topics in cancer research such as epigenetic drugs, CART cell-based new constructs and the application of artificial intelligence will be analyzed in view on introducing them to the clinical setting. Registration instructions Registration is free and can be made on-line at https://lnkd.in/ddt887Z6 The Congress is not by direct invitation of the Sponsor. #istitutotumorimilano #internationalexperts #immunooncology #newapproaches #molecularmechanism #neoplasticprogression #cancerresearch

🌟 We had a blast at the ESMO - European Society for Medical Oncology Asia Congress 2023! 🌟 NalaGenetics proudly engaged at the forefront of oncology innovation during the recent ESMO Asia Congress 2023 – a remarkable platform for the latest strides in cancer research and clinical advancements in the Asia-Pacific region! The conference showcased cutting-edge scientific breakthroughs focusing on prevalent cancer types in the Asia-Pacific area. The sessions were packed with invaluable multidisciplinary education, reflecting the collaboration of esteemed global and Asia-Pacific oncology associations. Our presentation, "What do women want to see in a personalized breast cancer risk report?", unveiled a qualitative study conducted in partnership with SJH Initiatives, led by the renowned surgical oncologist Dr. Samuel J. Haryono, SpB (K) Onk, National University Health System (NUHS), A*STAR - Agency for Science, Technology and Research, and UC Irvine. This presence came right after the launch of MammoReady™, our groundbreaking personalized breast cancer risk genetic test. With such strides, we envision a future where breast cancer management becomes more navigable. Thank you to ESMO Asia Congress 2023 for fostering groundbreaking discussions and innovations. Looking forward to future collaborations and continued strides towards revolutionizing oncology! Visit our website: www.nalagenetics.com ! #NalaGenetics #ESMOAsiaCongress2023 #PersonalizedHealthcare #Oncology

The newest edition of The Immuno-Oncology Digest has dropped in your inboxes, featuring the latest news and updates from across the PICI Network, as well as notable industry updates from breakthrough discoveries to research developments. In this issue, read about: →The appointments of new PICI Center Co-Directors, including Ansuman Satpathy, MD, PhD, Julia Carnevale, MD, and Saar Gill, MBBS, PhD, FRACP, at Stanford University School of Medicine, the University of California, San Francisco, and the University of Pennsylvania, respectively. →PICI’s additional $125 million commitment to boost research efforts, accelerate the development of innovative cancer immunotherapies and support our collaborative research model. →The first patient dosed in PICI portfolio company Georgiamune’s phase 1 clinical trial of GIM-531, a first-in-class selective T regulatory cell inhibitor. →Multiple immunotherapy research breakthroughs, including new publications from PICI Investigators, including Robert Schreiber, PhD, Washington University in St. Louis, James Allison, PhD, Director of the PICI Center at MD Anderson Cancer Center, Mohammad Rashidian, PhD, Kai Wucherpfennig, MD, PhD, and more!  Read the full issue and all the latest: https://lnkd.in/eWa9cBZP Subscribe for updates: https://lnkd.in/dEm2qHz